Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.58 and traded as high as $2.68. Brainstorm Cell Therapeutics shares last traded at $2.43, with a volume of 277,575 shares.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on the company. Maxim Group raised Brainstorm Cell Therapeutics from a "hold" rating to a "buy" rating and set a $2.00 price objective on the stock in a report on Thursday, July 11th. StockNews.com initiated coverage on Brainstorm Cell Therapeutics in a research note on Wednesday, October 9th. They set a "hold" rating on the stock.
View Our Latest Stock Report on Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Stock Performance
The stock's fifty day simple moving average is $0.86 and its two-hundred day simple moving average is $0.59. The stock has a market capitalization of $157.68 million, a P/E ratio of -7.03 and a beta of 0.33.
Brainstorm Cell Therapeutics (NASDAQ:BCLI - Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). During the same quarter in the prior year, the firm posted ($0.27) earnings per share. As a group, analysts expect that Brainstorm Cell Therapeutics Inc. will post -2.85 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Brainstorm Cell Therapeutics
An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 81,050 shares of the biotechnology company's stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics at the end of the most recent quarter. 14.33% of the stock is currently owned by hedge funds and other institutional investors.
Brainstorm Cell Therapeutics Company Profile
(
Get Free Report)
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
Featured Articles
Before you consider Brainstorm Cell Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brainstorm Cell Therapeutics wasn't on the list.
While Brainstorm Cell Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
